A Single-arm, Open-label, Phase 2 Study of Subcutaneous Isatuximab via On-Body Delivery System with Weekly Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)
September 11, 2026
A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET Alterations